These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15974908)

  • 1. C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease.
    DeBattista C; Belanoff J
    Curr Alzheimer Res; 2005 Apr; 2(2):125-9. PubMed ID: 15974908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone.
    Belanoff JK; Jurik J; Schatzberg LD; DeBattista C; Schatzberg AF
    J Mol Neurosci; 2002; 19(1-2):201-6. PubMed ID: 12212781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of mifepristone in the treatment of neuropsychiatric disorders.
    DeBattista C; Belanoff J
    Trends Endocrinol Metab; 2006 Apr; 17(3):117-21. PubMed ID: 16530421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New selective glucocorticoid receptor modulators reverse amyloid-β peptide-induced hippocampus toxicity.
    Pineau F; Canet G; Desrumaux C; Hunt H; Chevallier N; Ollivier M; Belanoff JK; Givalois L
    Neurobiol Aging; 2016 Sep; 45():109-122. PubMed ID: 27459932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of mifepristone (RU 486) on plasma cortisol in Alzheimer's disease.
    Pomara N; Hernando RT; de la Pena CB; Sidtis JJ; Cooper TB; Ferris S
    Neurochem Res; 2006 May; 31(5):585-8. PubMed ID: 16770728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mifepristone (RU 486) for Alzheimer's disease.
    Pomara N; Doraiswamy PM; Tun H; Ferris S
    Neurology; 2002 May; 58(9):1436. PubMed ID: 12011303
    [No Abstract]   [Full Text] [Related]  

  • 7. Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia.
    Gallagher P; Watson S; Elizabeth Dye C; Young AH; Nicol Ferrier I
    J Psychiatr Res; 2008 Oct; 42(12):1037-41. PubMed ID: 18255098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone.
    Fleseriu M; Molitch ME; Gross C; Schteingart DE; Vaughan TB; Biller BM
    Endocr Pract; 2013; 19(2):313-26. PubMed ID: 23337135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased glucocorticoid production and altered cortisol metabolism in women with mild to moderate Alzheimer's disease.
    Rasmuson S; Andrew R; Näsman B; Seckl JR; Walker BR; Olsson T
    Biol Psychiatry; 2001 Mar; 49(6):547-52. PubMed ID: 11257240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is mifepristone useful in psychotic depression?
    Carroll BJ; Rubin RT
    Neuropsychopharmacology; 2006 Dec; 31(12):2793-4; author reply 2795-7. PubMed ID: 17109015
    [No Abstract]   [Full Text] [Related]  

  • 11. Subchronic glucocorticoid receptor inhibition rescues early episodic memory and synaptic plasticity deficits in a mouse model of Alzheimer's disease.
    Lanté F; Chafai M; Raymond EF; Pereira AR; Mouska X; Kootar S; Barik J; Bethus I; Marie H
    Neuropsychopharmacology; 2015 Jun; 40(7):1772-81. PubMed ID: 25622751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in Gulf War veterans with chronic multisymptom illness.
    Golier JA; Caramanica K; Michaelides AC; Makotkine I; Schmeidler J; Harvey PD; Yehuda R
    Psychoneuroendocrinology; 2016 Feb; 64():22-30. PubMed ID: 26600007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men.
    Mattsson C; Reynolds RM; Simonyte K; Olsson T; Walker BR
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1347-52. PubMed ID: 19141586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia.
    Gallagher P; Watson S; Smith MS; Ferrier IN; Young AH
    Biol Psychiatry; 2005 Jan; 57(2):155-61. PubMed ID: 15652874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone.
    Lenze EJ; Hershey T; Newcomer JW; Karp JF; Blumberger D; Anger J; Doré P; Dixon D
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):962-9. PubMed ID: 24633761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone.
    Castinetti F; Conte-Devolx B; Brue T
    Neuroendocrinology; 2010; 92 Suppl 1():125-30. PubMed ID: 20829633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central and peripheral glucocorticoid receptors are involved in the plasma cortisol response to an acute stressor in rainbow trout.
    Alderman SL; McGuire A; Bernier NJ; Vijayan MM
    Gen Comp Endocrinol; 2012 Mar; 176(1):79-85. PubMed ID: 22233772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulsatile Cortisol Feedback on ACTH Secretion Is Mediated by the Glucocorticoid Receptor and Modulated by Gender.
    Roelfsema F; Aoun P; Veldhuis JD
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4094-4102. PubMed ID: 27548106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.
    Gross C; Blasey CM; Roe RL; Belanoff JK
    Obesity (Silver Spring); 2010 Dec; 18(12):2295-300. PubMed ID: 20339369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease.
    Relkin NR
    Expert Rev Neurother; 2007 Jun; 7(6):735-48. PubMed ID: 17561789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.